Hester Biosciences Ltd Technical Momentum Shifts Amid Bearish Signals

Technical Trend Overview and Price Movement

As of 23 March 2026, Hester Biosciences closed at ₹1,392.00, down 2.49% from the previous close of ₹1,427.50. The stock’s intraday range was between ₹1,392.00 and ₹1,443.90, reflecting heightened volatility. The 52-week high stands at ₹2,347.70, while the 52-week low is ₹1,246.75, indicating the stock is trading closer to its lower range, which aligns with the bearish technical signals.

The transition from a mildly bearish to a bearish technical trend suggests increasing selling pressure. This shift is corroborated by the daily moving averages, which remain firmly bearish, signalling that the stock price is consistently trading below key average price levels, a classic indicator of downward momentum.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD is mildly bullish, hinting at some short-term positive momentum or potential for a reversal. However, the monthly MACD remains bearish, underscoring a longer-term downtrend that has yet to be overcome. This divergence between weekly and monthly MACD readings suggests that while short-term traders might find some opportunities, the broader trend remains unfavourable.

Similarly, the Know Sure Thing (KST) indicator aligns with this mixed sentiment. It is mildly bullish on the weekly chart but bearish on the monthly timeframe, reinforcing the notion of short-term strength overshadowed by longer-term weakness.

RSI and Bollinger Bands Analysis

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, indicating neither overbought nor oversold conditions. This neutral RSI suggests that the stock is not yet at an extreme valuation level, but it also lacks the momentum to trigger a strong directional move based on this metric alone.

Conversely, Bollinger Bands on both weekly and monthly charts are bearish, signalling that the stock price is trending towards the lower band. This typically reflects increased volatility and downward pressure, which may continue to weigh on the stock price in the near term.

Volume and Dow Theory Insights

On-Balance Volume (OBV) is mildly bearish on the weekly chart, indicating that volume trends are not supporting price advances. The lack of a clear trend on the monthly OBV further emphasises the absence of strong buying interest. Dow Theory analysis shows no clear trend on the weekly timeframe but a mildly bullish trend on the monthly scale, adding another layer of complexity to the stock’s technical profile.

Comparative Returns and Market Context

When compared to the broader Sensex index, Hester Biosciences has underperformed over multiple time horizons. The stock’s one-month return is -10.79% versus the Sensex’s -10.00%, and year-to-date returns are -12.56% compared to the Sensex’s -12.54%. Over longer periods, the underperformance is more pronounced, with a three-year return of -17.31% against the Sensex’s 29.33%, and a five-year return of -22.00% versus the Sensex’s 49.49%. However, the stock has outperformed over a decade, delivering a 213.09% return compared to the Sensex’s 198.70%, reflecting some long-term value creation despite recent struggles.

Mojo Score and Ratings Update

MarketsMOJO assigns Hester Biosciences a Mojo Score of 37.0, categorising it with a Sell rating. This represents an upgrade from a previous Strong Sell rating as of 30 January 2026, signalling a slight improvement in the stock’s outlook but still reflecting significant caution. The micro-cap status of the company adds to the risk profile, as smaller companies often face greater volatility and liquidity challenges.

The downgrade in technical trend to bearish, combined with the Sell rating, suggests that investors should remain cautious and consider the stock’s risk-reward profile carefully before committing capital.

Moving Averages and Daily Technicals

Daily moving averages remain bearish, indicating that the stock price is consistently below its short- and medium-term averages. This technical configuration typically discourages buying interest and favours sellers. The absence of a positive crossover or upward momentum in moving averages further supports the bearish outlook.

Given the daily bearish moving averages and the mixed signals from weekly and monthly indicators, the stock appears to be in a consolidation phase with a downward bias, awaiting a catalyst to break either way.

Strategic Considerations for Investors

Investors analysing Hester Biosciences should weigh the mixed technical signals carefully. While weekly indicators such as MACD and KST show mild bullishness, the dominant monthly bearish signals and daily moving averages suggest that the stock remains under pressure. The neutral RSI and bearish Bollinger Bands imply that the stock is not yet oversold, leaving room for further downside.

Comparative underperformance against the Sensex over recent months and years adds to the cautious stance. However, the long-term outperformance over a decade indicates that patient investors with a high risk tolerance might find value if the company’s fundamentals improve or if a technical reversal materialises.

Conclusion: Navigating a Complex Technical Landscape

Hester Biosciences Ltd currently faces a challenging technical environment marked by bearish momentum and mixed indicator signals. The stock’s transition to a bearish trend, supported by daily moving averages and monthly MACD, suggests that caution is warranted. While some weekly indicators hint at short-term strength, these have yet to translate into a sustained upward move.

Investors should monitor key technical levels closely, particularly the 52-week low of ₹1,246.75, which may act as a support zone. A break below this level could accelerate the downtrend, while a recovery above daily moving averages and a shift in monthly MACD to bullish could signal a potential turnaround.

Given the micro-cap nature and current Mojo Grade of Sell, Hester Biosciences remains a speculative investment. A thorough evaluation of fundamental developments alongside technical signals is advisable before making investment decisions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today